Lupin Launches Tobramycin Inhalation Solution in US | CORPORATE ETHOS

Lupin Launches Tobramycin Inhalation Solution in US

By: | June 13, 2018
lupin

Jun 13: Mumbai-based pharma major Lupin Ltd on Wednesday announced the launch of its Tobramycin Inhalation Solution USP, having received an approval from the United States Food and Drug Administration (USFDA) earlier.

“Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa,” the company said in a BSE filing.

Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of approximately $99 million in the US (IQVIA MAT April 2018).